A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma.

Autor: Kuruvilla J; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Rushton C; Simon Fraser University, Burnaby, British Columbia, Canada., Villa D; BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, British Columbia, Canada., Aslam M; Hematology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada., Prica A; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Abdel Samad N; Hematology, The Moncton Hospital, Moncton, New Brunswick, Canada., Doucet S; Hematologic Oncology, CHUM-Hopital Notre-Dame, Montreal, Quebec, Canada., Dudebout J; Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada., Fleury I; Hematologic Oncology, Maisonneuve Rosemont Hospital, University of Montreal, Montreal, Quebec, Canada., Fraser G; Hematology, Juravinski Cancer Centre, Hamilton, Ontario, Canada., Larouche JF; CHU de Quebec-Universite Laval, Quebec City, Quebec, Canada., Shafey M; Alberta Health Services, University of Calgary, Calgary, Alberta, Canada., Skrabek P; Section of Hematology/Oncology Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada., Skamene T; Jewish General Hospital, Montreal, Quebec, Canada., Morin RD; Simon Fraser University, Burnaby, British Columbia, Canada., Alcaide M; Simon Fraser University, Burnaby, British Columbia, Canada., Ben-Neriah S; BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada., Lee D; Department of Medicine, Queen's University, Kingston, Ontario, Canada., Winch C; Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada., Shepherd LE; Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada., Scott DW; BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, British Columbia, Canada., Crump M; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Chen BE; Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada., Hay AE; Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada.

Publikováno v: British journal of haematology [Br J Haematol] 2024 Nov; Vol. 205 (5), pp. 2067-2071. Date of Electronic Publication: 2024 Sep 12.

Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP.

Autor: Stewart DA; Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada., Kuruvilla J; University Health Network, Princess Margaret Cancer Center, Toronto, Ontario, Canada., Lee D; Queens University, Kingston, Ontario, Canada., Dudebout JJ; Queens University, Kingston, Ontario, Canada., Chua N; Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada., Larouche JF; Hôpital Enfant-Jésus, Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada., Baetz T; Queens University, Kingston, Ontario, Canada., Shafey M; Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada., Abdel-Samad N; The Moncton Hospital, Moncton, New Brunswick, Canada., Robinson S; Queen Elizabeth II Health Science Center, Halifax, Nova Scotia, Canada., Fleury I; Maisonneuve-Rosemont Hospital, Institute of Hematology, Oncology and Cell Therapy, Montreal University, Montreal, Quebec, Canada., Fraser G; Juravinski Cancer Centre, McMaster University, Ontario, Hamilton, Canada., Skrabek P; Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada., Kukreti V; University Health Network, Princess Margaret Cancer Center, Toronto, Ontario, Canada., Kelly J; Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada., Hay AE; Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada., Shepherd LE; Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada., Chen BE; Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada., Crump M; University Health Network, Princess Margaret Cancer Center, Toronto, Ontario, Canada.

Publikováno v: British journal of haematology [Br J Haematol] 2024 Sep; Vol. 205 (3), pp. 881-890. Date of Electronic Publication: 2024 May 27.

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Autor: Morschhauser, Franck, Fowler, Nathan H, Feugier, Pierre, Bouabdallah, Reda, Tilly, Hervé, Palomba, M Lia, Fruchart, Christophe, Libby, Edward N, Casasnovas, Rene-Olivier, Flinn, Ian W, Haioun, Corinne, Maisonneuve, Hervé, Ysebaert, Loic, Bartlett, Nancy L, Bouabdallah, Kamal, Brice, Pauline, Ribrag, Vincent, Daguindau, Nicolas, Le Gouill, Steven, Pica, Gian M, Martin Garcia-Sancho, Alejandro, López-Guillermo, Armando, Larouche, Jean-François, Ando, Kiyoshi, Gomes da Silva, Maria, André, Marc, Zachée, Pierre, Sehn, Laurie H, Tobinai, Kensei, Cartron, Guillaume, Liu, David, Wang, Jianming, Xerri, Luc, Salles, Gilles A, Abdel-Samad N, Abdo-Matkiwsky M, Abraham J, Abrisqueta P, Anglaret B, Barnes JA, Benbrahim O, Bierman PJ, Bonnet C, Brault P, Bron D, Brooks BJ Jr, Byeff P, Casanova M, Cheung M, Choudhary Y, Comeau T, Cooper B, Couban S, Cox MC, Crump M, Deau Fischer B, Deconinck E, Deeren D, de la Cruz Vicente F, Delarue R, Del Campo R, Delmer A, Delwail V, Duggan PR, Eisenmann DJRM, El Yamani A, Eradat HA, Fabbro M, Farber C, Fisher DC, Fleischman RA, Fleck E, Fornecker LM, Foussard C, Gabarre J, Gaffar YA, Gallardo D, Ghazal H, Giagounidis A, Gill K, Glaisner S, Gonzalez H, Greenberg RH, Goubran Messiha H, Goy A, Gressin R, Gyan E, Hart LL, Hatake K, Hiddemann W, Hodossy B, Horkheimer I, Hoyer RJ, Huebel K, Ishikawa T, Izutsu K, Jardel H, Jhangiani HS, Johnson N, Joly B, Jourdan E, Kargar Samani K, Kato K, Kiguchi T, Kobayashi T, Kohser F, Koike M, Kouroukis C T, Laferriere N, Lamy de la Chapelle T, Landau DA, Lawler WE, Lemieux B, Levitan DA, Longree L, Lopez J, Mace J, Maerevoet M, Maigre M, Marjanovic Z, Michel J, Mounier C, Muntanola A, Ngirabacu MC, Nicolas-Virelizier E, Novelli S, Offner F, Palomera L, Pandit LH, Panwalkar A, Pierre P, Pignon JM, Pinto A, Plöger C, Pranger D, Quick DP, Reyes EA, Robin V, Robu D, Rodriguez Salazar MJ, Rosen PJ, Rosenbluth J, Sadot-Lebouvier S, Sangha R, Segota Z, Shapira I, Shtivelband M, Simon M, Soekler M, Soubeyran P, Taper J, Tereblo HR, Terol MJ, The AS, Ueda Y, van den Neste E, van Eygen K, van Hoof A, Vanstraelen G, Verner E, Warburton P, Yamamoto G, Yokoyama H, Zerazhi H, Zinzani PL.

Publikováno v: New England Journal of Medicine
New England Journal of Medicine, 2018, 379 (10), pp.934-947. ⟨10.1056/nejmoa1805104⟩
New England Journal of Medicine, Massachusetts Medical Society, 2018, 379 (10), pp.934-947. ⟨10.1056/nejmoa1805104⟩

International audience; BACKGROUND:Rituximab plus chemotherapy has been shown to be effective in patients with advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will have a relapse. Combination immunotherapy with l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3989a335983ccc37800421665ae98b9
http://hdl.handle.net/11585/674313

A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.

Autor: Cheung MC; Division of Hematology, Department of Medicine, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada; Canadian Cancer Trials Group, Queens University, Kingston, Canada. Electronic address: matthew.cheung@sunnybrook.ca., Mittmann N; Canadian Cancer Trials Group, Queens University, Kingston, Canada; Department of Pharmacology and Toxicology and Institute for Health Policy Management and Evaluation, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada., Owen C; Foothills Medical Centre and Tom Baker Cancer Centre, Calgary, Canada., Abdel-Samad N; Division of Hematology, The Moncton Hospital, Moncton, Canada., Fraser GAM; Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, Canada., Lam S; Victoria Hospital, Western University, London, Canada., Crump M; Canadian Cancer Trials Group, Queens University, Kingston, Canada; Division of Hematology, Department of Medicine, Princess Margaret Hospital and University of Toronto, Toronto, Canada., Sperlich C; Centre integre de Santé et de Services Sociaux de la Montérégie-Centre, Greenfield Park, Canada., van der Jagt R; Hematology, Ottawa Hospital, University of Ottawa, Ottawa, Canada., Prica A; Canadian Cancer Trials Group, Queens University, Kingston, Canada; Division of Hematology, Department of Medicine, Princess Margaret Hospital and University of Toronto, Toronto, Canada., Couban S; Canadian Cancer Trials Group, Queens University, Kingston, Canada; Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Canada., Woyach JA; Division of Hematology, The Ohio State University, Columbus, OH., Ruppert AS; Division of Hematology, The Ohio State University, Columbus, OH; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN., Booth AM; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; Department of Quantitative Health Sciences, and Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN., Mandrekar SJ; Department of Quantitative Health Sciences, and Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN., McDonald G; Canadian Cancer Trials Group, Queens University, Kingston, Canada., Shepherd LE; Department of Pharmacology and Toxicology and Institute for Health Policy Management and Evaluation, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada., Yen H; Canadian Cancer Trials Group, Queens University, Kingston, Canada., Chen BE; Canadian Cancer Trials Group, Queens University, Kingston, Canada., Hay AE; Canadian Cancer Trials Group, Queens University, Kingston, Canada; Department of Medicine, Queen's University, Kingston, Ontario, Canada.

Publikováno v: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2021 Nov; Vol. 21 (11), pp. 766-774. Date of Electronic Publication: 2021 Jul 03.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.